Skip to main content

Advertisement

SpringerLink
Log in

Exosome redux

  • News Feature
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

Adult stem cell companies are pivoting their businesses to commercialize exosomes as therapeutics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Different EV subtypes are depicted together with other co-isolated particles.

Author information

Authors and Affiliations

  1. Haddon Township, NJ, USA

    Mark Zipkin

Authors
  1. Mark Zipkin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zipkin, M. Exosome redux. Nat Biotechnol 37, 1395–1400 (2019). https://doi.org/10.1038/s41587-019-0326-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-019-0326-5

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation